Background Initial recurrence mapping of resected pancreatic ductal adenocarcinoma
(PDAC) could help in stratifying patient subpopulations for optimal postoperative follow-up …

Simple Summary Pancreatic ductal adenocarcinoma is a leading cause of cancer death
worldwide. Due to the frequently late diagnosis, early metastasis and high therapy …

Background Patients with lymph node (LN)-positive pancreatic ductal adenocarcinoma
(PDAC) have extremely poor survival rates. Circular RNAs (circRNAs), a newly discovered …

The efficacy of neoadjuvant therapy (NT) versus surgery first (SF) for pancreatic ductal
adenocarcinoma (PDAC) remains controversial. A random-effects meta-analysis of only …

Purpose: In research settings, circulating tumor DNA (ctDNA) shows promise as a tumor-
specific biomarker for pancreatic ductal adenocarcinoma (PDAC). This study aims to perform …

Objectives: Previous retrospective studies demonstrated that circulating tumor cells (CTCs)
subtypes correlate with overall survival in patients with pancreatic ductal adenocarcinoma …

The identification of circulating tumor cells (CTCs) relies on epithelial tumor cell markers. In
the present study, we aimed to determine whether cell-surface vimentin could be a …

The symposium “New criteria of resectability for pancreatic cancer” was held during the
33nd meeting of the Japanese Society of Hepato‐Biliary‐Pancreatic Surgery (JSHBPS) in …

Objective: To establish an evidence-based cutoff and predictors for early recurrence in
patients with resected locally advanced pancreatic cancer (LAPC). Background: It is unclear …

Objective: To develop an imaging-derived biomarker for prediction of overall survival (OS) of
pancreatic cancer by analyzing preoperative multiphase contrast-enhanced computed …